Enhancement of the antimicrobial properties of bacteriophage-K via stabilization using oil-in-water nano-emulsions

Biotechnology Progress

Volumn 30, Issue 4, 2014, Pages 932-944

  Esteban, Patricia Perez ^a,b   Alves, Diana R ^b   Enright, Mark C ^b   Bean, Jessica E ^b   Gaudion, Alison ^b   Jenkins, A T A ^b   Young, Amber E R ^c   Arnot, Tom C ^a  

^a University of Bath   (United Kingdom)

^b University of Bath   (United Kingdom)

^c FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Burn wound related infections; Oil in water nano emulsion; Phage therapy; Responsive wound dressings; S. aureus infections

Indexed keywords

BACTERIA; BIOCOMPATIBILITY; DESIGN OF EXPERIMENTS; EMULSIFICATION; EMULSIONS; ENZYME INHIBITION; PATIENT TREATMENT;

BURN WOUND-RELATED INFECTIONS; NANOEMULSION; PHAGE THERAPY; S. AUREUS; WOUND DRESSINGS;

BACTERIOPHAGES;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS AUREUS;

ANTIINFECTIVE AGENT; EMULSION; NANOCOMPOSITE; OIL; WATER;

ADMINISTRATION AND DOSAGE; BACTERIOPHAGE; CHEMISTRY; DRUG EFFECTS; EMULSION; HUMAN; PATHOGENICITY; STAPHYLOCOCCUS AUREUS; WOUND CLOSURE; WOUND HEALING;

ANTI-INFECTIVE AGENTS; BACTERIOPHAGES; EMULSIONS; HUMANS; NANOCOMPOSITES; OILS; STAPHYLOCOCCUS AUREUS; WATER; WOUND CLOSURE TECHNIQUES; WOUND HEALING;

EID: 84904738134     PISSN: 87567938     EISSN: 15206033     Source Type: Journal    
DOI: 10.1002/btpr.1898     Document Type: Article

References (54)

1. Alanis AJ. Resistance to antibiotics: are we in the post-antibiotic era? Arch Med Res. 2005;36:697-705.
2. Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resist Update. 2011;14:118-124.
3. Fung H, Kirschenbaum H, Ojofeitimi B. Linezolid: An oxazolidinone antimicrobial agent. Clin Ther. 2001;23:356-391.
4. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections. J Am Med Assoc. 2013;309:559-569.
5. Church D, Elsayed S, Reid O. Burn wound infections. Clin Microbiol Rev. 2006;19:403-434.
6. Fitzwater J, Purdue GF, Hunt JL, O'Keefe GE. The risk factors and time course of sepsis and organ dysfunction after burn trauma. J Trauma. 2003;54:959-966.
7. Griffiths HR, Thornton KL, Clements CM, Burge TS, Kay AR, Young AER. The cost of a hot drink scald. Burns. 2006;32:372-374.
8. Wolf SE, Rose JK, Desai MH, Mileski JP, Barrow RE, Herndon DN. Mortality determinants in massive pediatric burns. An analysis of 103 children with>or=80% TBSA burns (> or=70% full-thickness). Ann Surg. 1997;225:554-565; discussion 565-569.
9. Rashid A, Solomon LK, Lewis HG, Khan K. Outbreak of epidemic methicillin-resistant Staphylococcus aureus in a regional burns unit: management and implications. Burns. 2006;32:452-457.
10. Murray CK, Holmes RL, Ellis MW, et al. Twenty-five year epidemiology of invasive methicillin-resistant Staphylococcus aureus (MRSA) isolates recovered at a burn center. Burns. 2009;35:1112-1117.
11. Taylor PW, Stapleton PD, Paul Luzio J. New ways to treat bacterial infections. Drug Discov Today. 2002;7:1086-1091.
12. Nizet V, Ohtake T, Lauth X, et al. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature. 2001;414:454-457.
13. Kutateladze M, Adamia R. Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 2010;28:591-595.
14. Ahmad SI. Treatment of post-burns bacterial infections by bacteriophages, specifically ubiquitous Pseudomonas spp. notoriously resistant to antibiotics. Med Hypotheses. 2002;58:327-331.
15. Adhya S, Merril C. The road to phage therapy. Nature. 2006;443:754-755.
16. Hanlon GW. Bacteriophages: an appraisal of their role in the treatment of bacterial infections. Intl J Antimicrob Agents. 2007;30:118-128.
17. Ackermann H-W. 5500 Phages examined in the electron microscope. Arch Virol. 2007;152:227-243.
18. McVay CS, Velásquez M, Fralick JA. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob Agents Chemother. 2007;51:1934-1938.
19. Harper DR, Enright MC. Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J Appl Microbiol. 2011;111:1-7.
20. Carter MJ, Tingley-Kelley K, Warriner R a. Silver treatments and silver-impregnated dressings for the healing of leg wounds and ulcers: a systematic review and meta-analysis. J Am Acad Dermatol. 2010;63:668-679.
21. Bouchemal K, Briançon S, Perrier E, Fessi H. Nano-emulsion formulation using spontaneous emulsification: solvent, oil and surfactant optimisation. Intl J Pharm. 2004;280:241-251.
22. Prakash URT, Thiagarajan P. Nanoemulsions for drug delivery through different routes. Res Biotecnhol. 2011;2:1-13.
23. Azeem A, Khan ZI, Aqil M, Ahmad FJ, Khar RK, Talegaonkar S. Microemulsions as a surrogate carrier for dermal drug delivery. Drug Dev Ind Pharm. 2009;35:525-547.
24. Schramm LL. Emulsions, Foams, and Suspensions: Fundamentals and Applications. In: Biological and Medical Applications. Weinheim: WILEY-VCH Verlag GmbH & Co.KGaA; 2005:325-226.
25. Puapermpoonsiri U, Spencer J, van der Walle CF. A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur J Pharma Biopharma. 2009;72:26-33.
26. Kumari S, Harjai K, Chhibber S. Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by K. pneumoniae B5055. J Med Microbiol. 2011;60:205-210.
27. Capra ML, Patrignani F, Quiberoni ADL, Reinheimer JA, Lanciotti R, Guerzoni ME. Effect of high pressure homogenization on lactic acid bacteria phages and probiotic bacteria phages. Intl Dairy J. 2009;19:336-341.
28. Avsaroglu MD, Buzrul S, Alpas H, Akcelik M, Bozoglu F. Use of the Weibull model for lactococcal bacteriophage inactivation by high hydrostatic pressure. Intl J Food Microbiol. 2006;108:78-83.
29. Olson MR, Axler RP, Hicks RE. Effects of freezing and storage temperature on MS2 viability. J Virol Meth. 2004;122:147-52.
30. Jończyk E, Klak M, Miedzybrodzki R, Górski A. The influence of external factors on bacteriophages-review. Folia Microbiologica (Praha). 2011;56:191-200.
31. Iriarte FB, Balogh B, Momol MT, Smith LM, Wilson M, Jones JB. Factors affecting survival of bacteriophage on tomato leaf surfaces. Appl Environ Microbiol. 2007;73:1704-11.
32. Mylon SE, Rinciog CI, Schmidt N, Gutierrez L, Wong GCL, Nguyen TH. Influence of salts and natural organic matter on the stability of bacteriophage MS2. Langmuir. 2010;26:1035-1042.
33. Matsubara T, Emoto W, Kawashiro K. A simple two-transition model for loss of infectivity of phages on exposure to organic solvent. Biomol Eng. 2007;24:269-271.
34. Branston S, Stanley E, Ward J, Keshavarz-Moore E. Study of robustness of filamentous bacteriophages for industrial applications. Biotechnol Bioeng. 2011;108:1468-1472.
35. Tadros T, Izquierdo P, Esquena J. Formation and stability of nano-emulsions. Adv Coll Interf Sci. 2004:303-318.
36. Fernandez P, André V, Rieger J, Kühnle A. Nano-emulsion formation by emulsion phase inversion. Coll Surf. 2004;251:53-58.
37. Payne RJH, Jansen VAA. Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet. 2003;42:315-25.
38. Mason TG, Wilking JN, Meleson K, Chang CB, Graves SM. Nanoemulsions: formation, structure, and physical properties. J Phys. 2006;18:R635-R666.
39. Zwietering MH, Jongenburger I, Rombouts FM, van 't Riet K. Modeling of the bacterial growth curve. Appl Environ Microbiol. 1990;56:1875-1881.
40. Lindqvist R. Estimation of Staphylococcus aureus growth parameters from turbidity data: characterization of strain variation and comparison of methods. Appl Environ Microbiol. 2006;72:4862-4870.
41. Marino H. Phase Inversion Temperature Emulsification: From Batch to Continuous Process. 2010:142.
42. Langevin PB, Gravenstein N, Doyle TJ, et al. Growth of Staphylococcus aureus in Diprivan and Intralipid: implications on the pathogenesis of infections. Anesthesiology. 1999;91:1394-400.
43. Kim C, Lewis D, Kumar A. Bacterial and fungal growth in intravenous fat emulsions. Am J Health Sys Pharma. 1983;40:2159-2161.
44. Tessler M, Dascal A, Gioseffini S, Miller M, Mendelson J. Growth curves of Staphylococcus aureus, Candida albicans, and Moraxella osloensis in propofol and other media. Can J Anaesth. 1992;39:509-511.
45. Parker ML, Brocklehurst TF, Gunning PA, Coleman HP, Robins MM. Growth of food-borne pathogenic bacteria in oil-in-water emulsions: I--Methods for investigating the form of growth. J Appl Bacteriol. 1995;78:601-608.
46. Brocklehurst TF, Parker ML, Gunning PA, Coleman HP, Robins MM. Growth of food-borne pathogenic bacteria in oil-in-water emulsions: II--Effect of emulsion structure on growth parameters and form of growth. J Appl Bacteriol. 1995;78:609-615.
47. Prachaiyo P, McLandsborough L. Oil-in-water emulsion as a model system to study the growth of Escherichia coli O157: H7 in a heterogeneous food system. J Food Sci. 2003;68:1018-1024.
48. Li J, McClements DJ, McLandsborough LA. Interaction between emulsion droplets and Escherichia coli cells. J Food Microbiol Saf. 2001;66:570-574.
49. Kiss MM, Babineau EG, Bonatsakis M, et al. Phage ESCape: an emulsion-based approach for the selection of recombinant phage display antibodies. J Immunol Meth. 2011;367:17-26.
50. Fujito B, Lytle C. Elution of viruses by ionic and nonionic surfactants. Appl Environ Microbiol. 1996;62:3470-3473.
51. Pines O, Gutnick D. Specific binding of a bacteriophage at a hydrocarbon-water interface. J Bacteriol. 1984;157:179-183.
52. Payne RJH, Jansen V a a. Pharmacokinetic principles of bacteriophage therapy. Clin Pharmacokinet. 2003;42:315-25.
53. Payne R, Jansen V. Evidence for a phage proliferation threshold? J Virol. 2002;76:13123-13125.
54. Payne RJ, Phil D, Jansen V a. Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clin Pharmacol Ther. 2000;68:225-230.